Uncovering The Potential Therapeutic Applications of IGKV2-29

Target Name: IGKV2-29

NCBI ID: G28920

Uncovering The Potential Therapeutic Applications of IGKV2-29

IGKV2-29 (A18) is a protein that is expressed in various tissues throughout the body. It is a member of the IGK family of proteins, which are involved in the immune response. IGKV2-29 is unique because it is a spiky protein, with a unique arrangement of its amino acid residues.

One of the key functions of IGKV2-29 is its role in the immune response. It is involved in the development and maintenance of the adaptive immune system, which is the system that mounts an effective response to a pathogen after an initial infection.

IGKV2-29 plays a key role in this process by helping to ensure that the immune system is able to recognize and respond to foreign substances in the body. It does this by participating in the process of antigen presentation, which is the process by which the immune system recognizes and responds to the presence of a foreign substance in the body.

In addition to its role in the immune system, IGKV2-29 is also involved in the regulation of cellular processes in the body. For example, it has been shown to play a role in the regulation of cell division and in the development of cancer.

IGKV2-29 is also of interest as a potential drug target. Because it is involved in so many important cellular processes, it is a likely candidate for targeting with small molecules or other types of drugs. This is because targeting IGKV2-29 with a drug or other therapeutic agent could potentially have a wide range of potential therapeutic applications.

For example, IGKV2-29 could be used to treat a variety of diseases and conditions, including cancer, autoimmune diseases, and infections. Because it is involved in the regulation of cellular processes, it is possible that targeting IGKV2-29 with a drug could have a beneficial effect on the number and size of cancer cells, for example.

In addition to its potential therapeutic applications, IGKV2-29 is also of interest as a potential biomarker. Because it is a protein that is expressed in various tissues throughout the body, it is possible to use IGKV2-29 as a marker for the presence of certain diseases or conditions. This could be useful for the diagnosis and monitoring of disease, and could potentially lead to earlier detection of potential health problems.

Overall, IGKV2-29 is a protein that is of great interest due to its role in the immune response and its potential as a drug target and biomarker. Further research is needed to fully understand its unique properties and its potential therapeutic applications.

Protein Name: Immunoglobulin Kappa Variable 2-29

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets